STOCK TITAN

Shattuck Labs, Inc. Stock Price, News & Analysis

STTK Nasdaq

Welcome to our dedicated page for Shattuck Labs news (Ticker: STTK), a resource for investors and traders seeking the latest updates and insights on Shattuck Labs stock.

Shattuck Labs, Inc. (STTK) is a clinical-stage biotechnology company developing innovative dual-function fusion proteins targeting cancer and autoimmune diseases. This page serves as the definitive source for official company announcements, research milestones, and financial updates.

Investors and industry professionals will find timely updates on STTK's clinical trials, regulatory developments, and strategic partnerships. The curated news collection includes press releases on pipeline advancements, collaborations with pharmaceutical leaders, and progress across its proprietary ARC® platform programs.

Key content categories include updates on lead candidates like SL-172154, financial reporting disclosures, and scientific presentations. All materials are sourced directly from company communications to ensure accuracy and compliance.

Bookmark this page for streamlined access to STTK's latest developments in bi-functional therapeutics. Check regularly for critical updates impacting the company's position in immuno-oncology and autoimmune treatment innovation.

Rhea-AI Summary

Shattuck Labs (NASDAQ: STTK) presented two posters at the AACR Annual Meeting on promising therapeutic developments. The first poster showcased SL-9258, a TIGIT-Fc-LIGHT fusion protein, demonstrating effectiveness against PD1 resistance in tumor models. The second presentation detailed GADLEN™, a platform targeting gamma delta T cells to treat hematologic malignancies. CEO Taylor Schreiber emphasized the innovation and potential to address unmet medical needs in cancer treatment. These advancements highlight Shattuck's commitment to pioneering new biologic medicines for cancer and autoimmune diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.93%
Tags
-
Rhea-AI Summary

Shattuck Labs, Inc. (NASDAQ: STTK) will participate in the 20th Annual Needham Healthcare Conference held virtually from April 12-15, 2021. CEO Taylor Schreiber, M.D., Ph.D., and CFO Andrew Neill will present on April 14, 2021, at 11:00 a.m. EST in a fireside chat format. The event can be accessed through a live webcast, with a replay available for up to 90 days. Shattuck Labs focuses on developing bi-functional fusion proteins aimed at treating cancer and autoimmune diseases, with its lead candidate SL-172154 currently in a Phase 1 trial.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.76%
Tags
none
-
Rhea-AI Summary

Shattuck Labs (NASDAQ: STTK) announced the promotion of Andrew R. Neill to Chief Financial Officer, previously Vice President of Finance and Corporate Strategy. Neill is credited for his role in raising $330.5 million through recent financing efforts, which include Series B and B-1 financings and an IPO. CEO Taylor Schreiber emphasized Neill’s past contributions and strategic impact on advancing Shattuck's clinical-stage ARC compounds and GADLEN platform. Neill expressed enthusiasm for driving the company's growth in his new role, focusing on improving cancer treatment options.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.43%
Tags
management
Rhea-AI Summary

Shattuck Labs (NASDAQ: STTK) reported its Q4 and full-year 2020 financial results, revealing a cash position of $335.4 million as of December 31, compared to $39.1 million in 2019. R&D expenses rose to $9.8 million for Q4 2020, while G&A expenses increased to $3.6 million. The net loss for Q4 was $12.0 million, or $0.31 per share, versus $7.4 million, or $0.97 per share in the prior year. Shattuck anticipates Phase 1 trial data for its lead CD47 checkpoint inhibitor SL-172154 and PD-1 inhibitor SL-279252 in H2 2021, while projecting sufficient cash to fund operations through 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.43%
Tags
-
Rhea-AI Summary

Shattuck Labs, a clinical-stage biotechnology company, announced that two posters will be presented at the AACR Annual Meeting from April 10-15, 2021. The first poster focuses on preclinical data from its GADLEN™ platform, while the second discusses an in vivo model of checkpoint acquired resistance and the therapeutic potential of SL-9258 (TIGIT-Fc-LIGHT). Presenters include Dr. Suresh de Silva and Dr. George Fromm. The abstracts are numbered 1736 and 1697, respectively. Additional details will be available on the AACR website and Shattuck's Events & Presentations section post-event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.61%
Tags
conferences
-
Rhea-AI Summary

Shattuck Labs, Inc. (NASDAQ: STTK) announced its participation in two upcoming investor conferences. CEO Taylor Schreiber will speak at the Cowen 41st Annual Health Care Conference on March 2, 2021, and VP Andrew Neill will present at the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021. Shattuck is focused on developing bi-functional fusion proteins for cancer and autoimmune disease treatment, with its lead program SL-172154 currently in a Phase 1 trial. The company also collaborates with Takeda Pharmaceuticals on another candidate, SL-279252.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.32%
Tags
none
Rhea-AI Summary

Shattuck Labs, a clinical-stage biotechnology company (NASDAQ: STTK), announced its participation in Citi's 2021 Virtual Immuno-Oncology Day Conference on February 17-18, 2021. CEO Taylor Schreiber and VP of Finance Andrew Neill will present on the company's innovative bi-functional fusion proteins designed to treat cancer and autoimmune diseases. Shattuck's lead program, SL-172154, is currently undergoing a Phase 1 trial targeting the CD47 checkpoint, while a second program, SL-279252, is in collaboration with Takeda Pharmaceuticals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.1%
Tags
none
-
Rhea-AI Summary

Shattuck Labs, a clinical-stage biotechnology company listed on NASDAQ under the symbol STTK, announced its participation in the H.C. Wainwright BioConnect 2021 Conference, set for January 11-14, 2021. The presentation will be led by Andrew Neill, Vice President of Finance and Corporate Strategy, on January 11 at 6:00 a.m. EST. Attendees can access the session via a dedicated webcast link. Shattuck specializes in developing bi-functional fusion proteins for cancer and autoimmune disease treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.42%
Tags
conferences
-
Rhea-AI Summary

Shattuck Labs, a clinical-stage biotechnology company focused on bi-functional fusion proteins for cancer and autoimmune disease treatment, will present at the 39th Annual J.P. Morgan Healthcare Conference from January 11-14, 2021. CEO Taylor Schreiber will speak on January 14 at 5:20 p.m. EST. The presentation can be accessed live via webcast, with a replay available for 30 days. Shattuck's lead program is SL-172154, currently in Phase 1 trials, aiming to block the CD47 immune checkpoint while activating the CD40 pathway.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.91%
Tags
conferences
Rhea-AI Summary

Shattuck Labs, a clinical-stage biotechnology firm, announced its inclusion in the Russell 2000® and 3000® Indexes effective December 21, 2020. This milestone is seen as a reflection of investor confidence and is expected to enhance the company's visibility in the investment community, expanding its institutional shareholder base. The Russell indexes, managed by FTSE Russell, are pivotal for asset managers, with about $9 trillion in assets benchmarked against them. Shattuck specializes in bi-functional fusion proteins targeting cancer and autoimmune diseases, including ongoing Phase 1 trials for lead programs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.54%
Tags
none

FAQ

What is the current stock price of Shattuck Labs (STTK)?

The current stock price of Shattuck Labs (STTK) is $0.9808 as of August 29, 2025.

What is the market cap of Shattuck Labs (STTK)?

The market cap of Shattuck Labs (STTK) is approximately 47.9M.
Shattuck Labs, Inc.

Nasdaq:STTK

STTK Rankings

STTK Stock Data

47.90M
40.95M
14.36%
59.03%
0.9%
Biotechnology
Pharmaceutical Preparations
Link
United States
AUSTIN